Navigation Links
Novel radiotracer shines new light on the brains of Alzheimer's disease patients
Date:6/24/2010

A trial of a novel radioactive compound readily and safely distinguished the brains of Alzheimer's disease patients from healthy volunteers on brain scans and opens the doors to making such imaging available beyond facilities that can manufacture their own radioactive compounds. The results, reported by a Johns Hopkins team in the June Journal of Nuclear Medicine, could lead to better ways to distinguish Alzheimer's from other types of dementia, track disease progression and develop new therapeutics to fight the memory-ravaging disease.

Previously, the only way to peer into the brains of Alzheimer's patients was through autopsy or the use of another radioactive compound used in scans, or radiotracer, known as Pittsburgh compound or PIB. PIB is drawn to a protein known as beta-amyloid, which accumulates abnormally in the brains of Alzheimer's patients. However, PIB has a half-life of only 20 minutes, meaning that half of the substance degenerates every 20 minutes after it is made. Consequently, PIB's use is possible only at a few hospitals or academic medical centers with facilities to manufacture it since this compound degenerates so rapidly.

To solve this conundrum, Dean F. Wong, M.D., Ph.D., a professor of radiology and psychiatry at the Johns Hopkins University School of Medicine, and his colleagues looked to a new radiotracer known as 18F-AV-45 (also known as florbetapir F18). This compound, based on the radioactive isotope fluorine-18, is drawn to beta-amyloid like PIB. However, unlike PIB, florbetapir has a half-life of about 110 minutes, greatly increasing its ability to be transported significant distances away from manufacturing facilities.

Testing the new compound for the first time in humans, Wong and his colleagues recruited 26 volunteers 11 previously diagnosed with Alzheimer's disease, and 15 healthy subjects of similar age who performed normally on cognitive tests. Each of these volunteers received an injection of florbetapir, then received a PET scan of their brains. The brain scans, acquired over a 90-minute period, allowed the researchers to see the uptake of florbetapir in the brain over time.

Florbetapir had significantly heavier accumulation in the Alzheimer's patients' brains compared to the healthy volunteers, collecting in brain regions expected to be high in beta-amyloid deposits based on previous research. The results in AD patients were readily distinguishable from those of healthy subjects by 30 minutes after injection, and the differences continued for up to at least 90 minutes after injection of florbetapir. None of the AD patients or healthy volunteers suffered any ill effects from florbetapir and showed normal vital signs, electrocardiograms and blood-work after the scan.

"We could easily tell apart the two groups of patients. Those without Alzheimer's disease retained much less of the compound, and those with Alzheimer's disease retained much more of it," Wong says. "This is the first time we've been able to get results like this with a compound that can travel beyond the confines of a major academic medical center to the majority of the U.S. population."

Wong adds that florbetapir's portability could lead to numerous applications for this compound. For example, though Alzheimer's disease can usually be diagnosed from neurocognitive tests, imaging with florbetapir could help settle tricky cases in which patients might have other forms of dementia instead. The compound may also be useful in future studies designed to help solve current medical mysteries, such as which patients are most likely to progress from mild cognitive impairment to full-blown Alzheimer's disease.

Florbetapir may also be useful in trials of new experimental Alzheimer's therapeutics to measure their success, a purpose for which this compound is already being used on a limited basis, Wong says.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Team led by LA BioMed scientist develops novel approach to study neurological disorders
2. Novel paclitaxel formulation encouraging for treating advanced lung cancer
3. Novel Drug Combats Advanced Melanoma
4. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
5. Novel anti-malarial drug candidate found by UT Southwestern researchers
6. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
7. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
8. Third European Novel Food Approval Received by Tahitian Noni International
9. Novel nanoparticles prevent radiation damage
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel Method Eyed for Normalizing Blood Sugar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
Breaking Medicine Technology: